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Abstract
Background: A systems approach to understanding the etiology of schizophrenia requires a
theory which is able to integrate genetic as well as neurodevelopmental factors.
Presentation of the hypothesis: Based on a co-localization of loci approach and a large amount
of circumstantial evidence, we here propose that a functional deficiency of glial growth factors and
of growth factors produced by glial cells are among the distal causes in the genotype-to-phenotype
chain leading to the development of schizophrenia. These factors include neuregulin, insulin-like
growth factor I, insulin, epidermal growth factor, neurotrophic growth factors, erbB receptors,
phosphatidylinositol-3 kinase, growth arrest specific genes, neuritin, tumor necrosis factor alpha,
glutamate, NMDA and cholinergic receptors. A genetically and epigenetically determined low
baseline of glial growth factor signaling and synaptic strength is expected to increase the
vulnerability for additional reductions (e.g., by viruses such as HHV-6 and JC virus infecting glial
cells). This should lead to a weakening of the positive feedback loop between the presynaptic
neuron and its targets, and below a certain threshold to synaptic destabilization and schizophrenia.
Testing the hypothesis: Supported by informed conjectures and empirical facts, the hypothesis
makes an attractive case for a large number of further investigations.
Implications of the hypothesis: The hypothesis suggests glial cells as the locus of the genes-
environment interactions in schizophrenia, with glial asthenia as an important factor for the genetic
liability to the disorder, and an increase of prolactin and/or insulin as possible working mechanisms
of traditional and atypical neuroleptic treatments.
Background
The current understanding of the origin of schizophrenia
is mainly based on the multifactorial-threshold (MFT)
model of genetic liability and the neurodevelopmental
model [1]. The former is supported by family, twin, adop-
tion and modeling studies [2–4], and the latter by circum-
stantial evidence from clinical, epidemiological,
neuropathological, and imaging studies [5,6]. Growth de-
viations found in many cases of schizophrenia support
the neurodevelopmental hypothesis, e.g., low birth
weight, late maturation, leptosomatic body build, large
ventricles and low brain volume [5–8]). Neuronal growth
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and development [9,10] is controlled by growth factors
synthesized by glial cells [11]. Glial cell loss [12], de-
creased expression levels of glia- related genes [13], and
increased levels of S100B [14,15], a marker of glia cell in-
tegrity, has been observed in schizophrenia suggesting a
role for glial growth factors in the pathogenesis of the dis-
order.
Genome scans in schizophrenia have converged on sever-
al chromosomal locations [16]. A convergent loci ap-
proach has been proposed in the Proceedings of the
National Academy of Science USA as a technique for dis-
covering the molecular basis for a disease [17]. Conver-
gent techniques such as the convergent loci (CL) or the
convergent functional genomics approach [16,18,19]
search for agreement between the chromosomal position
of susceptibility genes for the disease and the function of
the genes discovered at that position. In convergent ap-
proaches, the function of the genes is usually defined as
evidence for their involvement in the disorder, derived
from non-linkage studies such as gene expression analyses
[16,18,19] or from evidence-based hypotheses such as the
neurodevelopmental hypothesis of schizophrenia. Be-
cause of the essential role of the GGF neuregulin for neu-
rodevelopment [20,21], we applied the CL approach to
schizophrenia linkage data and GGFs-related genes. In
our view, convergent techniques do not prove the exist-
ence of a causal relationship. However, they are useful
Figure 1
Pooled linkage results in schizophrenia and localization of genes related to glial growth factors and synaptic
strength. Data compiled from 60 published (not abstracts) linkage studies in schizophrenia (including two studies using endo-
phenotypes of the disorder) [73,74,146–203]. Each dot represents evidence for linkage obtained in an independent sample. The
level of significance is shown according to the criteria of Lander and Kruglyak [204]. Red indicates significant (lod score = 3.6),
yellow suggestive (lod score = 2.2) evidence and white hints (p ≤  0.05) for linkage. Only the marker showing the best evidence
for linkage in the region were used from each study. Markers within a distance of 20 Megabases (Mb) are displayed at the same
chromosomal position. The distance between linkage marker and gene in Mb is given below the gene. Chromosomal positions
were obtained from the Unified Database for Human Genome Mapping (UDB) [205] and the UCSC Human Genome Project
Working Draft  [http://genome.ucsc.edu]. A susceptibility gene within a distance of 20 Mb from a genetic marker can be
detected by linkage analysis. The marker-gene distances range from 0.1 to 19.1 (median 1.7) Mb.
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tools for the generation and preliminary testing of causal
hypotheses.
The GGFs deficiency hypothesis is part of the broader
working hypothesis of a decrease in the cerebral protein-
synthesis rate (CPRS) developed by one of us (HWM) as
result of his attempt to find a common denominator for
the diverse results of schizophrenia research [7]. The evo-
lutionary approach employed in the latter investigation
suggested that neuregulin 1 (NRG1) might be one of the
susceptibility genes for schizophrenia (Figure 1 in [7])
motivating further theoretical and experimental investiga-
tions. The hypothesis presented here provides a heuristic
explanation for the neurodevelopmental and genetic find-
ings in schizophrenia.
The function of glia and its growth factors
Glial cells play important roles in the developing [11] as
well as in the adult central nervous system (CNS). In the
adult CNS, glia has a supportive, a protective, a regenera-
tive, and an active regulatory role. Glia cells are sensors of
infection and produce cytokines to limit viral replication.
In adults, they induce neurogenesis in the hippocampus
and the subventricular zone [22], influence neuronal ac-
tivity and synaptic strength [23], and appear to be the
third partner in synaptic transmission (tripartite synapse)
[24]. Synaptic strength and cellular growth depend on the
synaptic and the general protein-synthesis rate [25,26]
which is influenced by growth factors such as neuro-
trophins and neuregulins [27,28]. Glial cells are part of a
positive feedback loop between presynaptic neurons and
their postsynaptic targets [29] involving neurotrophins
and neuregulins (NRGs).
NRGs are synthesized by neurons [11] and promote the
differentiation, survival and repair of the neuronal targets
such as glial cells [11], acetylcholine receptors [21], and
postsynaptic densities (PSD) in hippocampal neurons
[30]. Neuregulin-1 (NRG1) is concentrated at synaptic
sites suggesting a role in synapse-specific gene expression
[28]. Furthermore, NRGs influence the growth of neural
precursor cells, the radial migration of newborn neurons
during neocortex genesis, the rate of migration in a dose-
dependent manner [31], the interaction between pre- and
postsynaptic neurons during synaptogenesis including
neuromuscular synapse, activity-dependent maintenance
of synaptic connections, synaptic plasticity, long-term po-
tentiation, and the expression of ligand and voltage-gated
channels in central neurons [9,11,20,21,32–34]. NRGs
are also known as glial growth factor (GGF), Neu differen-
tiation factor (NDF), heregulin, sensory and motor neu-
ron derived factor (SMDF), and acetylcholine receptor
inducing activity (ARIA) [21].
Biochemically, NRGs are structurally related to what is
perhaps the best studied trophic factor – epidermal
growth factor (EGF) [11] and encode a large group of
polypeptide growth, survival and differentiation factors
[20,21] that all contain an extracellular epidermal growth
factor (EGF)-like domain, which is essential for their bio-
activity [35]. They are derived by alternative splicing from
four genes: NRG1, NRG2 also known as Don-1 and
NTAK, NRG3, and NRG4. NRG1-3 is expressed during
neurodevelopment and in the adult CNS [21], whereas
NRG4 transcripts have not been detected in neural tissue
[21]. The cytoplasmic tail of NRG interacts with the pro-
tein kinase LIM kinase 1 (LIMK1) [36].
NRGs act through a network of ErbB tyrosine kinase re-
ceptors consisting of ErbB1 (also termed EGF receptor or
HER1), ErbB2 (Neu/HER2), ErbB3 (HER3) and ErbB4
(HER4) [11,20,21,37]. NRGs bind to ErbB2-4, EGF and
transforming-growth factor alpha (TGFA) to ErbB1
[21,37]. ErbB receptors serve as docking sites for cytoplas-
mic signaling molecules such as Grb2-related adaptor pro-
tein 2 and phosphatidylinositol-3 kinase (PI3K) [21,37].
In addition, the ErbB receptor system integrates signaling
events from other receptor classes, such as G-protein-cou-
pled receptors and cytokine receptors [37].
NRGs induce the expression of growth factors, choliner-
gic, GABAergic and glutaminergic receptors (e.g., trans-
forming growth factor beta [21], N-methyl D-aspartate
(NMDA) receptor 2C subunit [21], gamma-amino butyric
acid (GABA) receptor beta-2 subunit [21], acetylcholine
receptor (AchR) alpha-5, alpha-7 [38], beta-4, delta and
epsilon subunits [21,39]. The promoter region of the nic-
otinic AchR epsilon subunit gene contains a NRG-respon-
sive element [39]. Furthermore, the NRG-dependent
regulation of AChRs at the neuromuscular junction (NMJ)
requires the serine/threonine cyclin-dependent kinase 5
regulatory subunit 1 (p35) [21].
NRGs appear to act synergistically with other growth fac-
tors such as insulin-like growth factor-I (IGF1) [40,41],
EGF [42], insulin [43], and growth arrest specific genes
(GAS6) [44–46]. In turn, neurotrophic growth factors
(e.g., BDNF and NT-3), glutamate, and neural activity in-
crease the expression of NRG [34,47] and of neuritin in
hippocampal and cortical neurons, regions well character-
ized in regard to synaptic plasticity [48].
With regard to the latter, ErbB receptors are enriched in
postsynaptic densities (PSD) and interact with other PSD
proteins such beta-2 syntrophin, NMDA receptor subunit
2C and 2B, Ca2+-activated potassium channels
[21,49,50], protein kinase C interacting protein (PICK1)
and glutamate (AMPA subtype) receptors [21].BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/8
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The synaptic connections are maintenanted by a positive
feedback loop between the presynaptic neuron and its tar-
gets which includes glial cells. The latter provide neuro-
trophins, e.g., GDNF, BDNF, NT-3, NT-4, hepatocyte
growth factor [11,34] that enhance neuronal survival, dif-
ferentiation, plasticity, pruning, synaptic strength and sta-
bilization, synaptic transmission, presynaptically by
increased secretion of neurotransmitters and postsynapti-
cally via NMDA receptors [9,11,51,52]. The synthesis of
neurotrophins is down regulated by inhibitory synaptic
activity (e.g., GABA), up regulated by neuregulin, activa-
tion of metabotropic glutamate group I receptors (mGlu-
RI), acetylcholine, physical exercise, physical and social
stress, cytokines, and neurotrophin itself [9,52–55]. Neu-
rotrophins are in short supply in the CNS [9]. Neurons
and axons that do not receive adequate amounts of neu-
rotrophic factors risk degeneration or synapse elimination
[9]. Neurotrophins are critical for long-term potentiation
(LTP) in the hippocampus and activity-dependent synap-
tic plasticity (SP), which are thought to be cellular models
for learning and memory [52].
GGFs such as NRG1, NGF, and EGF induce protein-syn-
thesis [56,57], which is required for cellular growth [25],
for activity-dependent maintenance of synaptic connec-
tions [58], synaptic strength [26], and long-term memory
[59].
Convergent loci
A search for convergent loci revealed 41 genes (see Fig. 1)
with related functions localized within significant or po-
tential linkage regions of schizophrenia (chromosomal
localization in parenthesis): neuregulin-1 (NRG1) (8),
neuregulin-2 (NRG2) (5), neuregulin-3 (NRG3) (10), ep-
idermal growth factor (EGF) (4), and neuregulin receptor
ErbB3 (12), transforming-growth factor alpha (TGFA) (2),
transforming-growth factor beta receptor II (TGFBR2) (3),
LIMK1 (7), Grb2-related adaptor protein 2 (22), phosph-
oinositide-3 kinase class 2 beta polypeptide (PIK3C2B)
(1), GABA receptor beta 2 (GABRB2) (5), acetylcholine re-
ceptor alpha 7 (CHRA7) (15) and epsilon (CHRNE) (17),
growth factors such as glial cell line derived neurotrophic
factor (GDNF) (5), GDNF receptor alpha 1 (GFRA1) (10),
GFRA2 (8), GFRA4 (20), GDNF family related persephin
(19), glutamate and its receptors (GRM1, metabotropic
glutamate receptor 1) (6), GRM4 (6) GRM5 (11) and
GRM6 (5), insulin-like growth factor I (IGF1) (12), insu-
lin receptor (INSR) (19), insulin receptor substrate 1
(IRS1) (2), GAS6 (13) and GAS5 (1), neuritin (6), syn-
trophin B2 (16), protein kinase C interacting protein
(PICK1) (22), NMDA receptor 2B (12) and 2 C (17), p35
(CDK5R1) (17). Furthermore, epiregulin (4) is a potent
pan-ErbB ligand [60]. Ephrins such as ephrin-B2 (13) and
ephrin-A5 (5) are involved in neurodevelopment, and in
the adult CNS in LTP, synaptic strength [61], and cell pro-
liferation of the adult subventricular zone [62]. Fibroblast
growth factors such as FGF2 (4) and indirectly the FGF
binding protein 1 (FGFBP1) (4) have a similar effect on
development, adult neurogenesis, cell survival and synap-
tic transmission [63,64]. Cytokines are neurotoxic or neu-
rotrophic [65]. For example, interleukin-8 (IL8) (4) exerts
neurotrophic effects on glial cells [65] and the latter con-
stitutively release tumor necrosis factor alpha (TNF) (6),
another cytokine, which markedly influences synaptic
strength [66] and leads to impaired insulin signaling via
ErbB2 and ErbB3 [67]. Moreover, interleukin-1 receptor
accessory protein-like 1 (X), a member of the IL1 receptor
family, is highly expressed in the adult hippocampus sug-
gesting a role in learning, memory, and synaptic strength
[68]. Neurogranin (11) is concentrated in the post-synap-
tic terminals of the hippocampus and involved in learn-
ing, LTP, and synaptic plasticity [69].
The convergent loci of the genes described above are dis-
played in Fig. 1 along with genetic markers showing some
evidence for linkage in schizophrenia. The inclusion of
significant as well as non-significant linkage markers may
well be the object of criticism if the intention were to
prove, rather than to generate in the context of discovery,
a hypothesis which has to be tested by other research pro-
grams. The convergences shown in Fig. 1 led us to propose
the following hypothesis for schizophrenia.
Presentation of the hypothesis
The growth factors deficiency and synaptic destabilization
hypothesis of schizophrenia (GGF/SD) states that a func-
tional deficiency of glial growth factors and of growth fac-
tors produced by glial cells such as neurotrophins and
glutamate (termed here GGFs) leading to a weakening of
the synaptic strength may be implicated as one of the im-
portant causes of schizophrenia (see Fig. 2).
The hypothesis suggests that glial cells might be the locus
of the genes-environment interactions in schizophrenia. A
genetically and epigenetically determined low glial
growth factor signaling and baseline synaptic strength are
expected to increase the vulnerability for additional reduc-
tions and for developing schizophrenia.
GGFs are part of a positive feedback mechanism for the
stabilization of synaptic connections. The baseline
strength or weakness of the synaptic connections is as-
sumed to be normally distributed in the general popula-
tion and to be influenced by factors relevant for growth,
that is by environmental as well as by genetic factors. In-
dividuals with a genetically and/or epigenetically deter-
mined weaker synaptic feedback mechanism display
differences in growth rate, brain development, matura-
tion, metabolism, personality, cognition, memory, risk
for neurodevelopmental disturbances and for schizophre-BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/8
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nia. A decrease of GGFs (e.g., at the end of brain growth
and at the beginning of menopause) might lead to the
negative symptoms observed in schizophrenia prodromes
[70,71].
The reduction of the synaptic strength below a certain
threshold is postulated to cause synaptic destabilization
and acute schizophrenic symptoms. Such a reduction
might result from specific genes, from the genetic back-
ground (e.g., anabolic hormones and general protein-syn-
thesis rate) or from environmental factors such as reduced
brain activity [34,47], neurotoxins or virus infections of
glial cells. An acute and pronounced deficiency of GGFs
causes axon withdrawal followed by regeneration and
synaptic remodelling. The probably incomplete regenera-
tion in individuals with a decreased functional activity of
GGFs might be responsible for the incomplete remissions
observed in schizophrenia.
Testing the hypothesis
Does the GGF/SD hypothesis fulfill the fundamental con-
ditions for a scientific hypothesis [72]: explanatory power
and testability?
Explanatory power
A scientifically useful hypothesis should explain the main
facts and be, at least, consistent with the rest of the facts
[72]. The GGF/SD hypothesis is able to explain major
findings of schizophrenia research such as (1) genetic
linkage, (2) neurodevelopmental disturbances, deviant
neuronal migration, (3) prenatal timing, (4) expression
studies, (5) multiorgan involvement, (6) growth devia-
tions, (7) seasonality of birth, (8) age of onset, (9) neuro-
degeneration, (9) regeneration and neural remodelling,
(11) memory disturbances, and (12) the maintenance of
the disorder in the population despite the reduced fertility
of the patients.
(1) Genetic linkage: The CHRNA7 gene on chromosome
15q shows evidence for linkage to schizophrenia [73,74]
and appears to be downstream of NRG because NRG leads
to an increase of alpha7 nicotinic acetylcholine receptors
(CHRNA7) and is highly expressed in cholinergic neurons
of the CNS [38]. The NRG1 gene itself is located within a
linkage region of schizophrenia on 8p. Further conver-
gences seem to exist (see Fig. 1). Moreover, reported asso-
ciations of schizophrenia with 5-HT receptor 2A [75], 5-
HT5A [76], NT-3 [77], metabotropic glutamate receptor
subtype 5 [78], NOTCH4 [79], possibly NRG1 [80], po-
tassium channel gene hKCa3 [81], proline dehydrogenase
(oxidase) PRODH2 [82,83], and regulator of G-protein
signaling 4 (RGS4) [8,84] are all in agreement with the hy-
pothesis. NRG1 is a glial growth factor which interacts
with Ca2+-activated potassium channels [21,49,50].
Notch plays a role in gliogenesis [85]. NT-3 is produced by
glial cells [11,34]. 5-HT increases the release of glial gluta-
mate [86]. Proline oxidase appears to catalyze the first step
of an alternative route for glutamate production in glial
cells of the hippocampus [87]. The receptors for EGF and
neuregulins, the ErbB receptor system, integrates also the
signal transduction from G-protein-coupled receptors
[37], which is inhibited by RGS4 [88]. However, some of
the findings cited in this paragraph and shown in Fig. 1
are very probably false positives.
(2) Neurodevelopment: evidence for glial cell abnormali-
ties, neurodevelopmental disturbances, neuronal migra-
tion, and cognitive disturbances has been found in
schizophrenia [6,12,13]. Glial cells play an important role
Figure 2
The glial growth factors deficiency and synaptic
destabilization hypothesis of schizophrenia. The
hypothesis is depicted in form of the multifactorial-threshold
model for schizophrenia developed by Gottesman and
Shields [206] and postulates that several genes (e.g., NRG1,
TNF, GAS6, INF1 etc.) and environmental factors influence
the positive feedback loop between the presynaptic neuron
and its target cells. The hypothesis assumes that the baseline
strength of synaptic connections is normally distributed in
the general population, such that those whose synaptic
strength falls below a certain threshold develop synaptic
destabilization and schizophrenic symptoms. The strength of
the growth signaling correlates with the efficacy and stability
of the synaptic connection. Environmental and genetic fac-
tors increase or decrease growth signaling and in conse-
quence synaptic strength. Viruses may cause synaptic
destabilization by triggering the release of neurotoxic
cytokines from glial cells or by decreasing the synthesis of
GGFs via a reduction of the protein-synthesis rate in viral
infected glial cells.
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in neurodevelopment and neuronal migration [11,89],
and the highest ratio of glia-to-neurons is found in the ne-
ocortex suggesting a key role for glial cells in higher cogni-
tive functions [90].
(3) Prenatal timing: NRG is important for midgestation
[20,21], a prenatal period with evidence for neurodevel-
opmental disturbances in schizophrenia [6].
(4) Expression studies in postmortem brains are also in
line with the postulated functional deficiency of GGFs.
Since GGFs are involved in growth, they should influence
the expression of many genes. Indeed, a large number of
decreased mRNAs or proteins has been reported in schiz-
ophrenia (for review [7], e.g., synapsin, synaptophysin,
glutamate receptors, somatostatin, glutamic acid decar-
boxylase, protein kinase C, adenylate cyclase, regulator of
G-protein signaling 4 (RGS4) [19], MAP kinase phos-
phatase MKP2, postsynaptic density protein 95 growth as-
sociated protein-43, and alpha7-nicotinic receptor [91]).
A functional GGFs deficiency could also explain the re-
sults of a gene expression analysis suggesting a glial cell
deficiency in schizophrenia [13].
(5) Multiorgan involvement has been observed in schizo-
phrenia, e.g., brain, blood vessels (nailfold plexus), lung
(cancer, TBC), immune system (lymphocytes, rheumatoid
arthritis), and skin (dermatoglyphics) (for review [7]).
These findings are in line with the expression of NRG in
neurons, glia, heart, liver, stomach, lung, kidney, immune
system, and skin [11,20], of GAS6 in an equal number of
tissues including rheumatoid artheritis [92], and finally
with the role of the ErbB receptors in growth regulation in
a wide variety of cell types [20].
(6) Growth deviations have been observed in schizophre-
nia [5–8]. NRGs are growth factors and act synergistically
on glial cells with the insulin-like growth factor I (IGF1)
[93], a major determinant of fetal growth [94] as well as
with GAS6, which is involved in bone formation and glial
growth [44,95]. In addition, the reported negative associ-
ation between schizophrenia and cancer [96,97] agrees
with the role of ErbB receptors in the genesis of carcino-
mas [20].
(7) Seasonality of birth: The increase of IGF1 in the sum-
mer [94] might account for the seasonality of birth in
schizophrenia [98]. IGF2 is imprinted in humans
[99,100]. Imprinted genes often help to regulate the
growth of the fetus [101]. Growth regulatory signals lead
to histone acetylation and hence epigenetic variation of
gene expression [102].
(8) Age of onset: Brain growth might be used as an indi-
rect indicator of the activity of GGFs. Fig. 3 shows that a
decrease in head and brain growth is accompanied by a
sharp increase in the risk for developing schizophrenia.
(9) Neurodegeneration: Disruption of the NRG1 gene
causes neuronal degeneration after initial synapse forma-
tion, especially in motor neurons, [33,103]. Degeneration
of the second motor neuron does also take place in schiz-
ophrenia causing atrophy of skeletal muscle fibres, a
mechanism elucidated by Meltzer in the search for the
cause of increased serum CK, a muscle-derived enzyme, in
acute psychosis [104,105]. Furthermore, a GGFs deficien-
cy would explain the increased levels of S100B, a marker
of glial cell integrity, in acute schizophrenia [14,15] and
the evidence for a minor neurodegenerative process in
chronic schizophrenic patients revealed by longitudinal
MRI studies [106].
(10) Regeneration: NRG is important for neuronal regen-
eration following environmental insults [21]. A genetical-
ly or epigenetically determined deficiency of GGFs is
compatible with the limited regeneration of motor neu-
rons observed in schizophrenia [104,105] and with the
incomplete remission of the disorder, which is the foun-
dation of Kraepelin's schizophrenia (dementia praecox)
concept.
(11) Memory disturbances: In the adult brain, NRGs and
neurotrophins appear to be involved in activity-depend-
ent synaptic plasticity [30,48,51,107], a mechanism rele-
Figure 3
Brain growth and the age at onset of schizophrenia.
The end of head and brain growth, presumably associated
with a decline in growth factors, marks the beginning of the
age of onset in schizophrenia. Data from [2,207]. The growth
curve is supported by results from developmental studies of
brain metabolism and of brain volume [10,208]. In addition,
several studies have reported smaller head size at birth in
individuals who later developed schizophrenia compared to
controls (for review [8]).BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/8
Page 7 of 14
(page number not for citation purposes)
vant to protein-synthesis dependent long-term memory
[59]. They are expressed in brain regions well character-
ized in regard to synaptic plasticity (hippocampus and
cortex). Memory impairment has been found in schizo-
phrenia and appears to be responsible for the characteris-
tic symptoms of the disorder [108].
(12) The maintenance of schizophrenia in the population
despite the reduced fertility of the patients [109] is a par-
tially unsolved puzzle [110] which might be explained by
the postulated growth deficiency. Growth-dependent
birth weight is the classical example for stabilizing selec-
tion in humans [111], a selection against both extremes.
We conclude that the postulated GGFs deficiency and syn-
aptic destabilization in schizophrenia fulfils the first req-
uisite for a scientific hypothesis, to explain the main facts.
However, is the hypothesis also consistent with the rest of
the facts? For such a test, an extensive list of 84 major find-
ings of schizophrenia research has been compiled by one
of us (HWM) from the literature using books and review
articles for literature from 1900 to 1975, PubMed's and
PsycLit's electronic databases for publications from 1966
to 2001 and from 1974 to 2001, respectively [7]. A major
finding was defined operationally as results obtained by at
least two independent groups of researchers. The GGF/SD
hypothesis appears to be consistent with the major find-
ings in schizophrenia.
Testability
The second fundamental condition for a scientific hy-
pothesis is to be susceptible to verification and refutation
and to aid in the prediction of new facts and relationships
[72].
The GGF/SD hypothesis can be verified or falsified by
searching for concomitant variations between the postu-
lated independent and the dependent variables, that is be-
tween concentration or signal transduction of GGFs such
as NRG, IGF1, GAS6, TNF-alpha, neuritin etc. and schizo-
phrenia or schizophrenia-like symptoms. The independ-
ent variables can be measured in animals or humans, and
the dependent variable in animal models of the disease
endophenotypes or in acute schizophrenic psychosis,
preferably with elevated serum CK or S100B. The different
parameters of GGFs can be investigated at different levels
and by different methods, e.g., by studying mRNA, pro-
teins or signal transduction and by using knock-out ani-
mals, antisense mRNA, cDNA microarrays, antibodies or
signal transduction assays in immune cells, fibroblasts or
muscle cells from patients. A confounding variable might
be the large number of alternatively spliced NRGs.
Furthermore, deductive reasoning from the hypothesis
leads to certain logical consequences that can be tested.
The hypothesis predictions include, among others, (1) a
reduction of neurotrophins and synaptic strength induced
by virus infections of glial cells, (2) the involvement of
risk genes for schizophrenia in the pathway of GGFs and/
or synaptic strength (SS), (3) differences in the structure
and function of organs influenced by NRG, (4) a de-
creased synaptic protein-synthesis rate, decreased SS, and
synaptic destabilization as a common final pathway, and
(5) synaptic stabilization via improvement of astroglia
function as an antipsychotic drug mechanism.
(1) The predicted reduction of neurotrophins/SS by acute,
latent, or reactivated virus infections can be investigated
in animal models or glial cell cultures. Glial cells display
genetically determined individual differences to virus in-
fections [112] and are infected by a large number of virus-
es (for review [113,114]). Especially interesting in this
regard is the human herpes virus-6 (HHV-6) and the JC vi-
rus (JCV). The HHV-6 infects worldwide, within the first
two years of life, nearly 100% of the human population,
infects predominantly glial cells with a low-level of viral
production [115], persists latently lifelong, and has been
detected in 13% – 74% of normal human brains [116–
118]. The JCV infects more than 70% of the world's pop-
ulation during early childhood [119], infects mainly glial
cells (oligodendrocytes as well as astrocytes) [114,120],
remains in the latent state without apparent clinical symp-
toms but shows in vitro the ability to deregulate the cellu-
lar function of oligodendrocytes and perhaps astrocytes
[121,122]. The JC virus is spread by urban sewage
[119,123] which might contribute to the urban factor ob-
served in schizophrenia (for review [8]).
(2) Another prediction is that some of the GGF- and SS-
related genes increase the risk for schizophrenia. Such
genes (e.g., Fig. 1) can be tested for allelic association
(linkage disequilibrium, LD) with schizophrenia. Since
LD studies in complex disorders have often identified reg-
ulatory regions influencing the disease [124], and since
different parts of the same gene are not necessarily in LD
with each other (e.g., [125]), candidate genes for schizo-
phrenia and their regulatory regions will have to be inves-
tigated by haplotypes consisting of densely spaced SNPs.
Under optimal circumstances, sample sizes of more than
500 affecteds appear to be required to detect LD in com-
plex disorders such as schizophrenia [126,127]. Optimal
circumstances are present, when a single disease-causing
mutation accounts for a large proportion of the phenotyp-
ic variance and has arisen recently on a relatively uncom-
mon haplotype background [128]. Such favorable
circumstances rarely exist in schizophrenia. Locus and al-
lelic heterogeneity are common in complex disorders,
produce dramatic decreases in power [128], and an in-
crease in sample size (e.g., [129] or by meta-analysis
[130]) further increases heterogeneity [124]. Therefore,BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/8
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the frequent elusiveness of positional cloning results in
complex disorders is hardly surprising [124,131]. Given
the inefficiency of LD studies [124,132] and the generally
low repeatability of positive findings in complex disorders
[127], negative results of LD studies are, unfortunately,
unable to disprove anything. To falsify the hypothesis, it
might be necessary to investigate protein concentrations
and to perform functional assays of cells derived from
schizophrenic patients and their relatives.
(3) The multiorgan expression of GGFs such as NRG,
GAS6 and their receptors predicts differences in the struc-
ture and function of relevant organs such as liver, skin,
heart, lung, kidney, bones, muscle, sensory and motor
neurons, and acetycholine receptor density at the NMJ.
For example, a decrease of muscle mass, of muscular-
growth rate, of bone structure, and an increase of the risk
for liver cirrhosis are predicted for schizophrenic patients,
their family members and for introversion, an associated
personality trait [7].
(4) A decreased rate of glial, neuronal or synaptic protein
synthesis is predicted by the GGF/SD hypothesis based on
the facts that NRGs, GAS6, and other GGFs are growth fac-
tors, that NRGs result in an increased synthesis of growth
factors, that growth is associated with protein synthesis,
and that NRG1 stimulates the protein-synthesis rate
[7,56].
(5) Finally, the GGF/SD hypothesis predicts an antipsy-
chotic effect by reducing the synaptic destabilization via
the improvement of astroglial function. The prediction
can be tested by stimulation of the synaptic protein syn-
thesis rate, e.g., via glial growth factors such as NRGs, neu-
rotrophins, EGF, IGF1, insulin, prolactin, activation of
ErbB receptors or PI3K. Hyperprolactinemia via
dopamine receptor blockade is a well known "side-effect"
of traditional neuroleptics [133]. Dopamine receptor
blockade and/or elevation of prolactin levels have also
been reported for atypical antipsychotics such as clozap-
ine [133], olanzapine [133], risperdone [134], amisul-
pride [135,136], ziprasidone [137], and zotepine [138].
Furthermore, clozapine and olanzapine increase the level
of insulin [139–141]. This suggests that an increase of
prolactin and/or insulin might be the working mecha-
nism of neuroleptics. Hence, an augmentation of antipsy-
chotic efficacy is predicted by combining neuroleptics
with a predominant insulin profile with others showing a
marked hyperprolactinemia. The latter prediction can be
easily tested, e.g., by combining clozapine or olanzapine
with amisulpride in the treatment of acute schizophrenic
psychosis.
Implications of the hypothesis
A major weakness of the hypothesis outlined above is that
it is based on circumstantial evidence. However, "the hy-
pothesis is the principal intellectual instrument in re-
search" [72] and it is an "utterly misleading view that
knowledge can be advanced by merely collecting facts"
[209]. An advantage of the present hypothesis is that it not
only fulfils the two fundamental conditions for a useful
scientific hypothesis – explanatory power and testability -
, but that it also provides a unifying explanation for sever-
al diverse findings in schizophrenia. Furthermore, it is in
agreement with other hypotheses, e.g., the polygenic [2],
epigenetic [142], virus [143], nicotinergic [91], glutamate
[144,145], synaptic plasticity, cerebral protein-synthesis
rate [7], and neurodevelopmental hypotheses [5,6,8]. If
the hypothesis of synaptic destabilization by a functional
deficiency of pathways involved in GGFs is eventually
proven by a comprehensive research program, it will pro-
vide a path for the rational design of preventive and ther-
apeutic interventions.
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After the manuscript had been accepted, Kendler and co-
workers reported an interesting finding which is in agree-
ment with the synaptic destabilization hypothesis pre-
sented here, an allelic association between the human
dysbindin gene DTNBP1 and schizophrenia. According to
the authors, the dysbindin gene seems to influence the
synaptic function. See, RE Straub et al. Genetic VariationBMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/8
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in the 6p22.3 Gene DTNBP1, the human Ortholog of the
mouse Dysbindin, Is Associated with Schizophrenia. Am J
Hum Genet 2002 Jul 3;71 (2).  [http://genomebiolo-
gy.com/resolver.asp?PubMedID=12098102]
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